GlassScriptPhysician profile
Bridget Shaffer Morris
NPI 1952959140
$977.30
in general payments reported to CMS, 2019-2025
19 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.90 · 2022: $69.17 · 2023: $207 · 2024: $197 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $340.74 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $97.60 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $68.81 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $55.19 | 2025 | Terlivaz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.88 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.77 | 2023 | Cyltezo |
| Pfizer INC. | $44.19 | 2025 | |
| Exact Sciences Corporation | $41.63 | 2025 | The Cologuard Plus Collection Kit |
| Organon LLC | $38.92 | 2022-2023 | Renflexis |
| Qol Medical, LLC | $34.59 | 2024 | Sucraid |
| Intercept Pharmaceuticals, INC. | $23.62 | 2023 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $22.95 | 2025 | Iqirvo |
| Celltrion USA INC. | $18.37 | 2025 | Vegzelma |
| Janssen Biotech, INC. | $17.86 | 2025 | Tremfya |
| Braintree Laboratories, INC. | $16.73 | 2024 | Suflave, Sutab |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16.71 | 2025 | |
| Phathom Pharmaceuticals, INC. | $16.37 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $16.18 | 2024 | Zinplava, Dificid |
| Ferring Pharmaceuticals INC. | $15.19 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.